Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group
- 11 April 2006
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 133 (4), 389-396
- https://doi.org/10.1111/j.1365-2141.2006.06042.x
Abstract
The value of intensive therapy, including autologous stem cell transplantation, in newly diagnosed myeloma patients >60 years is not clear. We evaluated the impact of age (<60 years vs. 60-64 years) on survival in a prospective, population-based setting and compared survival with conventionally treated historic controls. The prospective population comprised 452 patients registered between 1998 and 2000. Of these, 414 received intensive therapy. The historic population, derived from our most recent population-based study on conventional therapy, comprised 281 patients. Of these, 243 fulfilled our eligibility criteria for intensive therapy. For patients undergoing intensive therapy it was found that two factors, beta-2-microglobulin and age <60 years vs. 60-64 years, had independent prognostic impact on survival. However, compared with the historic controls a survival advantage was found both for patients <60 (median 66 months vs. 43 months, P < 0.001) and 60-64 years (median 50 months vs. 27 months; P = 0.001). We conclude that in a population-based setting higher age adversely influences outcome after intensive therapy. Our results indicate that intensive therapy prolongs survival also at age 60-64 years but with less superiority than in younger patients.Keywords
This publication has 20 references indexed in Scilit:
- High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-AutogreffeJournal of Clinical Oncology, 2005
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialBlood, 2004
- Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of ageBone Marrow Transplantation, 2003
- Hematopoietic stem cell transplantation for hematological malignancies in EuropeLeukemia, 2003
- The role of autologous transplantation in patients with multiple myeloma aged 65 years and overBone Marrow Transplantation, 2000
- Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factorsBritish Journal of Haematology, 1999
- Long‐term survival in multiple myeloma: a Finnish Leukaemia Group studyBritish Journal of Haematology, 1999
- Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decadesEuropean Journal of Haematology, 1999
- Has the incidence of multiple myeloma in old age been underestimated?European Journal of Haematology, 1991
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983